Alexander N. Shoushtari, MD
Clinical Director, Melanoma Service; Member, Cellular Therapy Service
Melanoma; Acral Melanoma; Mucosal Melanoma; Uveal Melanoma; Cell Therapy; Clinical Trials of Targeted or Immune-Based Therapies
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Shoushtari accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Rush Medical College
Internal Medicine - University of Chicago Medical Center
Medical Oncology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist who exclusively sees people with melanoma, and I have the largest practice in our Melanoma Service. Each year, I see approximately 155 new patients with melanoma and conduct nearly 1,400 patient visits.
Within the global melanoma community, I am best known for treating patients with acral, mucosal, and uveal (eye) melanomas. These less common types of melanoma arise in the eye or on hairless surfaces of the body and can often be more difficult to treat than the more common skin melanomas. I work hard with our world-class surgeons, dermatologists, and radiation specialists to coordinate interdisciplinary, team-based care that gets patients the best possible results.
Treatment for melanoma, like much of modern medicine, is changing quickly and is becoming more sub-specialized. This is generally a very good thing; it ensures doctors like me are at the cutting edge of care for your melanoma. Sometimes, however, navigating a cancer diagnosis and its treatment options can feel like an endless maze of appointments. I became a medical oncologist to help lead people through this difficult process. The foundation of excellent cancer care is good communication. I am a child of two immigrants, so I know how confusing, complicated, and rushed medical interactions can feel when doctors use a lot of jargon and type their notes while they are in the room with you. I pride myself not only on clear, compassionate communication, but also on giving people the time they need to process information. This ensures we can make the best decisions on how to manage melanoma together. When my patients and their loved ones finish an appointment with me, they can expect to understand what is happening with their cancer, what the next steps are in their medical care, and what the months and years ahead will look like.
Our Melanoma Service is passionate about giving people with melanoma access to the best new treatment options. I recently led MSK’s trials of tebentafusp, the first FDA-approved therapy specifically for uveal melanoma. I am proud to say that MSK was one of the first places in the world to offer tebentafusp to patients with this type of melanoma. More recently, I was appointed to MSK’s Cellular Therapy Service to treat patients with tumor infiltrating lymphocyte (TIL) therapy, an experimental cell therapy that has shown promise for melanomas that do not respond to standard immune therapy. My scientific publications focus on the new drugs we test in clinic and how we can use a patient’s genetic information to understand if they might benefit from treatment and why.
When I am not working or sleeping, I am usually spending time with loved ones or trying to improve my Brazilian Jiu-Jitsu.
Awards and Honors
- Wings of Hope Award, Melanoma Research Foundation
- Young Investigator Award, American Society of Clinical Oncology
- Junior Investigator Award, Ocular Melanoma Foundation
- Clinical Trials Investigated by Dr. Shoushtari
- A Phase I Study of FHD-286 in People with Uveal Melanoma
- A Phase I/II Study of DYP688 for People with Advanced Uveal Melanoma and Other Melanomas with GNAQ/11 Gene Mutations
- A Phase I/IIA Study of LNS8801 with and without Pembrolizumab Immunotherapy in People with Advanced Melanoma
- A Phase II Study of Axitinib/Nivolumab Alone and with Ipilimumab or Radiation Therapy to Treat Previously Untreated Advanced Mucosal Melanoma
- A Phase II Study of Nemvaleukin Alfa in People with Cutaneous Melanoma or Mucosal Melanoma
- A Phase II Study of Nivolumab Immunotherapy Alone and with Cabozantinib to Prevent Mucosal Melanoma Relapse after Surgery
- Clinical Trials Co-Investigated by Dr. Shoushtari
- A Phase IB Study of Belvarafenib Alone and in Combination with Cobimetinib in People with Advanced Melanoma Who Had Immunotherapy
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Shoushtari’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alexander N. Shoushtari discloses the following relationships and financial interests:
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.